<DOC>
	<DOCNO>NCT00182052</DOCNO>
	<brief_summary>The purpose study learn effect ( good bad ) rosiglitazone patient prostate cancer . This study go look effect rosiglitazone prostate specific antigen ( PSA ) level .</brief_summary>
	<brief_title>Rosiglitazone ( Avandia ) v . Placebo Androgen Dependent Prostate Cancer</brief_title>
	<detailed_description>- Patients randomly assign initial treatment either rosiglitazone placebo orally twice daily , every day long disease progression serious side effect . Patients ask complete drug log keep track medication . - Before treatment begin follow test perform : physical exam ; bone scan ; blood work ( include PSA level test ) urine sample . - While study follow test procedure do month : review side effect routine blood test ( include PSA level ) . - While study follow test procedure do month 2 4 : review side effect ; routine blood test ( include PSA level ) urine test . - If patient 's disease progress treatment code broken patient placebo , option begin take rosiglitazone .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate Biochemical disease progression follow local therapy define three rise PSA PSA determination least 4 week apart PSA value &gt; = 0.2ng/ml For men treat radical prostatectomy , PSA &gt; = 2 ng/ml For men treat primary radiation therapy postprostatectomy radiation therapy , PSA &gt; = 2 ng/ml &gt; 150 % postradiation nadir Not appropriate candidate salvage radiation therapy salvage prostatectomy Baseline PSADT &lt; 24 month CALGB performance status 0,1 2 Metastatic disease Prior hormonal therapy recurrent prostate cancer Prior chemotherapy prostate cancer Current treatment insulin oral hypoglycemic History treatment thiazolidinediones Radiation therapy within 6 month SGOT &gt; 1.5 x ULN Fasting blood glucose &lt; 60 mg/dl NYHA Class 3 4 cardiac status</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>rosiglitazone</keyword>
	<keyword>Avandia</keyword>
	<keyword>androgen dependant prostate cancer</keyword>
</DOC>